

PHARMACOLOGY

Pharmacological Management
for Diabetes Mellitus

Independent Study Course 28.4.2

Melissa Bednarek, PT, DPT, PhD, CCS

Chatham University
Pittsburgh, PA



CONTINUING PHYSICAL THERAPY EDUCATION

ACADEMY OF
ORTHOPAEDIC
PHYSICAL THERAPY

 **APTA**
American Physical Therapy Association

REFERENCES

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed April 4, 2018.
2. Gladson B. *Pharmacology for Rehabilitation Professionals*. 2nd ed. St. Louis, MO: Elsevier Saunders; 2011.
3. Navale AM, Paranjape AN. Glucose transporters: physiological and pathological roles. *Biophys Rev*. 2016;8(1):5-9. doi: 10.1007/s12551-015-0186-2.
4. UpToDate. McCulloch DK. Insulin therapy in type 2 diabetes mellitus. www.uptodate.com/contents/insulin-therapy-in-type-2-diabetes-mellitus. Accessed March 9, 2018.
5. American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2018. *Diabetes Care*. 2018;41(Suppl 1):S13-S27. doi: 10.2337/dc18-S002.
6. American Diabetes Association. Diagnosing diabetes and learning about prediabetes. www.diabetes.org/diabetes-basics/diagnosis/. Accessed March 10, 2018.
7. Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. *Phys Ther*. 2008;88(11):1322-1335. doi: 10.2522/ptj.20080008. Epub 2008 Sep 18.
8. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Panel Treatment III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Panel Treatment III) Final Report. *Circulation*. 2002;106(25):3143-3421.
9. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med*. 1998;339(4):229-234.
10. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. *Diabet Med*. 2009;26(2):142-148.
11. Fox CS, Golden SH, Anderson C, et al. Update on prevention of cardiovascular disease in adults with Type 2 diabetes mellitus in light of recent evidence: A scientific statement from the American Heart Association and the American Diabetes Association. *Circulation*. 2015;132(8):691-718. doi: 10.1161/CIR.000000000000230. Epub 2015 Aug 5.
12. American Diabetes Association. 6. Glycemic targets: Standards of Medical Care in Diabetes-2018. *Diabetes Care*. 2018;41(Suppl 1):S55-S64. doi: 10.2337/dc18-S006.
13. Skyler JS, Bergenstal R, Bonow RO, et al. American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. *Diabetes Care*. 2009;32(1):187-192. doi: 10.2337/dc08-9026. Epub 2008 Dec 17.
14. Pernicova I, Korbonits M. Metformin--mode of action and clinical implications for diabetes and cancer. *Nat Rev Endocrinol*. 2014;10(3):143-156. doi: 10.1038/nren- do.2013.256. Epub 2014 Jan 7.
15. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. *N Engl J Med*. 1995;333(9):550-554.
16. Lee JO, Lee SK, Kim JH, et al. Metformin regulates glucose transporter 4 (GLUT4) translocation through AMP-activated protein kinase (AMPK)-mediated Cbl/CAP signaling in 3T3-L1 preadipocyte cells. *J Biol Chem*. 2012;287(53):44121-44129. doi: 10.1074/jbc.M112.361386. Epub 2012 Nov 7.
17. Wu MS, Johnston P, Sheu WH, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. *Diabetes Care*. 1990;13(1):1-8.
18. UpToDate. McCulloch DK. Sulfonylureas and meglitinides in the treatment of diabetes mellitus. www.uptodate.com/contents/sulfonylureas-and-meglitinides-in-the-treatment-of-diabetes-mellitus. Accessed March 11, 2018.
19. UpToDate. McCulloch DK. Thiazolidinediones in the treatment of diabetes mellitus. www.uptodate.com/contents/thiazolidinediones-in-the-treatment-of-diabetes-mellitus. Accessed March 23, 2018.
20. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. *Arch Intern Med*. 2004;164(19):2097-2104.
21. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones. *Diabetologia*. 2008;51(1):8-11. doi.org/10.1007/s00125-007-0873-z.
22. Habib ZA, Havstad SL, Wells K, Divine G, Pladevall M, Williams LK. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. *J Clin Endocrinol Metab*. 2010;95(2):592-600. doi: 10.1210/jc.2009-1385. Epub 2010 Jan 8.

23. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). *Diabetes Care*. 1999;22(6):960-964.
24. UpToDate. McCulloch DK. Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes. www.uptodate.com/contents/alpha-glucosidase-inhibitors-and-lipase-inhibitors-for-treatment-of-diabetes-mellitus. Accessed March 23, 2018.
25. Kazafeos K. Incretin effect: GLP-1, GIP, DPP4. *Diabetes Res Clin Pract*. 2011;93(Suppl 1):S32-S36.
26. UpToDate. Dungan K, DeSantis A. Dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus. www.uptodate.com/contents/dipeptidyl-peptidase-4-dpp-4-inhibitors-for-the-treatment-of-type-2-diabetes-mellitus. Accessed March 24, 2018.
27. UpToDate. DeSantis A. Sodium-glucose co-transporter 2 inhibitors for the treatment of type 2 diabetes mellitus. www.uptodate.com/contents/sodium-glucose-co-transporter-2-inhibitors-for-the-treatment-of-type-2-diabetes-mellitus. Accessed March 25, 2018.
28. UpToDate. Dungan K, DeSantis A. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus. www.uptodate.com/contents/glucagon-like-peptide-1-receptor-agonists-for-the-treatment-of-type-2-diabetes-mellitus. Accessed March 24, 2018.
29. Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. *Diabetes Care*. 2007;30(11):2767-2772.
30. UpToDate. Dungan K. Amylin analogs for the treatment of diabetes mellitus. www.uptodate.com/contents/amylan-analogs-for-the-treatment-of-diabetes-mellitus. Accessed March 24, 2018.
31. UpToDate. McCulloch DK. General principles of insulin therapy in diabetes mellitus. www.uptodate.com/contents/general-principles-of-insulin-therapy-in-diabetes-mellitus. Accessed March 25, 2018.
32. UpToDate. Pittas AG. Inhaled insulin therapy in diabetes mellitus. www.uptodate.com/contents/inhaled-insulin-therapy-in-diabetes-mellitus. Accessed March 25, 2018.
33. UpToDate. McCulloch DK. Initial management of blood glucose in adults with type 2 diabetes mellitus. www.uptodate.com/contents/initial-management-of-blood-glucose-in-adults-with-type-2-diabetes-mellitus. Accessed March 25, 2018.
34. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2015;38(1):140-149. doi: 10.2337/dc14-2441.
35. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2018. *Diabetes Care*. 2018;41(Suppl 1):S73-S85. doi: 10.2337/dc18-S008.
36. Colberg SR, Sigal RJ, Fernhall B, et al. Exercise and Type 2 Diabetes: The American College of Sports Medicine and the American Diabetes Association: joint position statement. *Diabetes Care*. 2010;33(12): e147-e167. doi: 10.2337/dc10-9990.
37. UpToDate. McCulloch DK. Effects of exercise in adults with diabetes mellitus. www.uptodate.com/contents/effects-of-exercise-in-adults-with-diabetes-mellitus. Accessed March 25, 2018.
38. Cuff DJ, Meneilly GS, Martin A, Ignaszewski A, Tildesley HD, Frohlich JJ. Effective exercise modality to reduce insulin resistance in women with type 2 diabetes. *Diabetes Care*. 2003;26(11):2977-2982.
39. Umpierre D, Ribeiro PA, Kramer CK, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. *JAMA*. 2011;305(17):1790-1799. doi: 10.1001/jama.2011.576.